US EditionFaron reports increased remission rate in trial for myelodysplastic syndrome candidate - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Faron reports increased remission rate in trial for myelodysplastic syndrome candidate - Pharmafile
Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in its ongoing phase 1/2 BEXMAB trial. The updated data show a CR rate of 43% – up from 28% in an earlier analysis – reinforcing the promise of its candidate as a therapy for this […] The post Faron reports increased remission rate in trial for myelodysplastic syndrome candidate appeared first on Ph…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium